198 related articles for article (PubMed ID: 28416487)
1. Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging.
Sans M; Gharpure K; Tibshirani R; Zhang J; Liang L; Liu J; Young JH; Dood RL; Sood AK; Eberlin LS
Cancer Res; 2017 Jun; 77(11):2903-2913. PubMed ID: 28416487
[TBL] [Abstract][Full Text] [Related]
2. Targeted Mass Spectrometry of Longitudinal Patient Sera Reveals LTBP1 as a Potential Surveillance Biomarker for High-Grade Serous Ovarian Carcinoma.
Wenk D; Khan S; Ignatchenko V; May T; Bernardini MQ; Kislinger T
J Proteome Res; 2024 Feb; 23(2):749-759. PubMed ID: 38266179
[TBL] [Abstract][Full Text] [Related]
3. High density of CXCL12-positive immune cell infiltration predicts chemosensitivity and recurrence-free survival in ovarian carcinoma.
Köhn P; Lalos A; Posabella A; Wilhelm A; Tampakis A; Caner E; Güth U; Stadlmann S; Spagnoli GC; Piscuoglio S; Richarz S; Delko T; Droeser RA; Singer G
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17943-17955. PubMed ID: 37966614
[TBL] [Abstract][Full Text] [Related]
4. Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma.
Hu Y; Pan J; Shah P; Ao M; Thomas SN; Liu Y; Chen L; Schnaubelt M; Clark DJ; Rodriguez H; Boja ES; Hiltke T; Kinsinger CR; Rodland KD; Li QK; Qian J; Zhang Z; Chan DW; Zhang H;
Cell Rep; 2020 Oct; 33(3):108276. PubMed ID: 33086064
[TBL] [Abstract][Full Text] [Related]
5. Spatial Transcriptomics Depict Ligand-Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors.
Ferri-Borgogno S; Zhu Y; Sheng J; Burks JK; Gomez JA; Wong KK; Wong STC; Mok SC
Cancer Res; 2023 May; 83(9):1503-1516. PubMed ID: 36787106
[TBL] [Abstract][Full Text] [Related]
6. A Multistep Tumor Growth Model of High-Grade Serous Ovarian Carcinoma Identifies Hypoxia-Associated Signatures.
More MH; Varankar SS; Naik RR; Dhake RD; Ray P; Bankar RM; Mali AM; Subbalakshmi AR; Chakraborty P; Jolly MK; Bapat SA
Cells Tissues Organs; 2024; 213(2):79-95. PubMed ID: 35970135
[TBL] [Abstract][Full Text] [Related]
7. Survivin expression at the mRNA level in tumors and the protein concentration in the serum and peritoneal fluid in patients with serous ovarian tumors.
Kruszniewska-Rajs C; Smycz-Kubanska M; Strzalka-Mrozik B; Strzelczyk J; Szanecki W; Witek A; Gola J; Mielczarek-Palacz A
Ginekol Pol; 2023; 94(6):435-441. PubMed ID: 36929784
[TBL] [Abstract][Full Text] [Related]
8. Serous surface papillary borderline ovarian tumors: correlation of sonographic features with clinic pathological findings.
Wang D; Su N; Wang R; Zhang L; Qi Z; Liu Z; Yang J; Leng J; Xiang Y;
Ultrasound Obstet Gynecol; 2024 May; 63(5):691-698. PubMed ID: 37592848
[TBL] [Abstract][Full Text] [Related]
9. Evidence for Diverse Prognosis in High-Grade Serous Ovarian Carcinoma: Solid, Pseudoendometrioid, and Transitional-Like; So-Called "SET Morphology" and Progesterone Receptor Status.
Uner H; Demir M; Goksuluk D; Kars A; Uner M; Usubutun A
Turk Patoloji Derg; 2022; 38(3):240-250. PubMed ID: 35147976
[TBL] [Abstract][Full Text] [Related]
10. Identification of metabolic biomarkers for diagnosis of epithelial ovarian cancer using internal extraction electrospray ionization mass spectrometry (iEESI-MS).
Li J; Wang Z; Liu W; Tan L; Yu Y; Liu D; Wei Z; Zhang S
Cancer Biomark; 2023; 37(2):67-84. PubMed ID: 37248885
[TBL] [Abstract][Full Text] [Related]
11. Improved overall survival in patients with high-grade serous ovarian cancer is associated with CD16a+ immunologic neighborhoods containing NK cells, T cells and macrophages.
Nersesian S; Arseneau RJ; Mejia JP; Lee SN; Westhaver LP; Griffiths NW; Grantham SR; Meunier L; Communal L; Mukherjee A; Mes-Masson AM; Arnason T; Nelson BH; Boudreau JE
Front Immunol; 2023; 14():1307873. PubMed ID: 38318505
[TBL] [Abstract][Full Text] [Related]
12. High-throughput approaches for precision medicine in high-grade serous ovarian cancer.
Govindarajan M; Wohlmuth C; Waas M; Bernardini MQ; Kislinger T
J Hematol Oncol; 2020 Oct; 13(1):134. PubMed ID: 33036656
[TBL] [Abstract][Full Text] [Related]
13. Ambient Ionization and FAIMS Mass Spectrometry for Enhanced Imaging of Multiply Charged Molecular Ions in Biological Tissues.
Feider CL; Elizondo N; Eberlin LS
Anal Chem; 2016 Dec; 88(23):11533-11541. PubMed ID: 27782388
[TBL] [Abstract][Full Text] [Related]
14. Role of magnetic resonance imaging to differentiate between borderline and malignant serous epithelial ovarian tumors.
Akçay A; Peker AA; Oran Z; Toprak H; Toluk Ö; Balsak S; Badur BA; Gültekin MA
Abdom Radiol (NY); 2024 Jan; 49(1):229-236. PubMed ID: 37857912
[TBL] [Abstract][Full Text] [Related]
15. Trps1 predicts poor prognosis in advanced high grade serous ovarian carcinoma.
Wang X; Sun J; Liu Y; Lin Z; Jiang X; Ye Y; Lv C; Lian X; Xu W; Luo S; Liao S; Chen Z; Wang S
Int J Cancer; 2024 May; 154(9):1639-1651. PubMed ID: 38212905
[TBL] [Abstract][Full Text] [Related]
16. Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer.
Burdett NL; Willis MO; Alsop K; Hunt AL; Pandey A; Hamilton PT; Abulez T; Liu X; Hoang T; Craig S; Fereday S; Hendley J; Garsed DW; Milne K; Kalaria S; Marshall A; Hood BL; Wilson KN; Conrads KA; Pishas KI; Ananda S; Scott CL; Antill Y; McNally O; Mileshkin L; Hamilton A; Au-Yeung G; Devereux L; Thorne H; Bild A; Bateman NW; Maxwell GL; Chang JT; Conrads TP; Nelson BH; Bowtell DDL; Christie EL
Nat Genet; 2023 Mar; 55(3):437-450. PubMed ID: 36849657
[TBL] [Abstract][Full Text] [Related]
17. Multivariate statistical differentiation of renal cell carcinomas based on lipidomic analysis by ambient ionization imaging mass spectrometry.
Dill AL; Eberlin LS; Zheng C; Costa AB; Ifa DR; Cheng L; Masterson TA; Koch MO; Vitek O; Cooks RG
Anal Bioanal Chem; 2010 Dec; 398(7-8):2969-78. PubMed ID: 20953777
[TBL] [Abstract][Full Text] [Related]
18. In situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapy.
Corvigno S; Badal S; Spradlin ML; Keating M; Pereira I; Stur E; Bayraktar E; Foster KI; Bateman NW; Barakat W; Darcy KM; Conrads TP; Maxwell GL; Lorenzi PL; Lutgendorf SK; Wen Y; Zhao L; Thaker PH; Goodheart MJ; Liu J; Fleming N; Lee S; Eberlin LS; Sood AK
NPJ Precis Oncol; 2023 Nov; 7(1):115. PubMed ID: 37923835
[TBL] [Abstract][Full Text] [Related]
19. Ultrahigh Resolution Lipid Mass Spectrometry Imaging of High-Grade Serous Ovarian Cancer Mouse Models.
Ma X; Botros A; Yun SR; Park EY; Kim O; Chen R; Palaniappan M; Matzuk MM; Kim J; Fernández FM
bioRxiv; 2023 Nov; ():. PubMed ID: 37961688
[TBL] [Abstract][Full Text] [Related]
20. Exploring the cellular and molecular differences between ovarian clear cell carcinoma and high-grade serous carcinoma using single-cell RNA sequencing and GEO gene expression signatures.
Guo D; Zhang S; Gao Y; Shi J; Wang X; Zhang Z; Zhang Y; Wang Y; Zhao K; Li M; Wang A; Wang P; Gou Y; Zhang M; Liu M; Zhang Y; Chen R; Sun J; Wang S; Wu X; Liang Z; Chen J; Lang J
Cell Biosci; 2023 Jul; 13(1):139. PubMed ID: 37525249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
